Related Experiment Video
Updated: Jun 25, 2025
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Effect of PAWI-2 on pancreatic cancer stem cell tumors
John R Cashman1, Emily A Cashman2
1Human BioMolecular Research Institute, San Diego, 5310 Eastgate Mall, San Diego, CA, 92121, USA. jcashman@hbri.org.
Abstract:
Worldwide, pancreatic cancer (PC) is a major health problem and almost 0.5 million people were diagnosed with PC in 2020. In the United States, more than 64,000 adults will be diagnosed with PC in 2023. PC is highly resistant to currently available treatments and standard of care chemotherapies cause serious side effects. Most PC patients are resistant to clinical therapies. Combination therapy has showed superior efficacy over single-agent treatment. However, most therapy has failed to show a significant improvement in overall survival due to treatment-related toxicity. Developing efficacious clinically useful PC therapies remains a challenge. Herein, we show the efficacy of an innovative pathway modulator, p53-Activator Wnt Inhibitor-2 (PAWI-2) against tumors arising from human pancreatic cancer stem cells (i.e., hPCSCs, FGβ3 cells). PAWI-2 is a potent inhibitor of tumor growth. In the present study, we showed PAWI-2 potently inhibited growth of tumors from hPCSCs in orthopic xenograft models of both male and female mice. PAWI-2 worked in a non-toxic manner to inhibit tumors. Compared to vehicle-treated animals, PAWI-2 modulated molecular regulators of tumors. Anti-cancer results showed PAWI-2 in vivo efficacy could be correlated to in vitro potency to inhibit FGβ3 cells. PAWI-2 represents a safe, new approach to combat PC.
Insights
A novel drug, p53-Activator Wnt Inhibitor-2 (PAWI-2), effectively inhibits pancreatic cancer growth in preclinical models. This non-toxic compound shows promise as a new treatment for pancreatic cancer stem cells.
Area of Science:
- Oncology
- Cancer Biology
- Drug Discovery
Background:
- Pancreatic cancer (PC) presents a significant global health challenge with limited effective treatments.
- Current therapies often exhibit resistance and severe side effects, necessitating novel therapeutic strategies.
- Developing safe and effective treatments for PC, particularly targeting cancer stem cells, remains a critical unmet need.
Purpose of the Study:
- To evaluate the efficacy of p53-Activator Wnt Inhibitor-2 (PAWI-2) against human pancreatic cancer stem cells (hPCSCs).
- To assess the in vivo anti-tumor activity and safety profile of PAWI-2 in preclinical models.
Main Methods:
- Utilized orthotopic xenograft models in male and female mice to test PAWI-2 efficacy.
- Assessed in vitro potency of PAWI-2 against FGβ3 cells (hPCSCs).
- Monitored tumor growth inhibition and molecular regulator modulation by PAWI-2.
Main Results:
- PAWI-2 demonstrated potent inhibition of tumor growth originating from hPCSCs in vivo.
- The anti-cancer effects observed in vivo correlated with PAWI-2's in vitro potency against FGβ3 cells.
- PAWI-2 exhibited a non-toxic profile, modulating key molecular regulators of tumor growth.
Conclusions:
- PAWI-2 is an effective inhibitor of pancreatic cancer growth driven by hPCSCs.
- PAWI-2 represents a promising, safe, and innovative therapeutic agent for pancreatic cancer.
- Further clinical investigation of PAWI-2 for pancreatic cancer treatment is warranted.
